Date: 2026-04-02 FY ends: December (calendar year) Market cap: ~$2.81B | P/S (TTM): 5.7x | Revenue growth: 110.3% YoY (FY25) Shares outstanding: 90.9M Data source: Scout brief 2026-04-01 | Atlas baseline 2026-04-01
Atlas scored TVTX as a 4/5 conviction play with a PEG of 0.05, calling it "deeply discounted to the growth rate." I largely agree with Atlas's numbers — the financial profile is genuinely impressive. Where I diverge is on the risk weighting. Atlas acknowledges the FSGS binary risk and competitive intensification but ultimately leans into the valuation gap as the dominant signal. I want to stress-test that framing.
The numbers have to match the theory. And in this case, the numbers are excellent — but the theory depends heavily on a single FDA decision 11 days from now.
Specialty pharma focused on rare kidney diseases. One commercial drug (FILSPARI/sparsentan) for IgA nephropathy (IgAN), approved February 2023. Legacy product (tiopronin) for cystinosis, declining. Pipeline includes FSGS label expansion (PDUFA April 13, 2026), pegtibatinase for HCU (Phase 3), and post-transplant IgAN study (SPARX). CSL Vifor partnership for ex-US rights generates milestones.
| Quarter | Revenue ($M) | YoY % | QoQ % | FILSPARI ($M) | FILSPARI QoQ | License ($M) | GM% [GAAP] |
|---|---|---|---|---|---|---|---|
| Q1 FY24 | 41.4 | 34.0% | -8.2% | 19.8 | — | 1.5 | 96.4% |
| Q2 FY24 | 54.1 | 68.0% | 30.7% | 27.1 | +37% | 1.9 | 96.1% |
| Q3 FY24 | 62.9 | 69.5% | 16.3% | 35.6 | +31% | 1.9 | 97.5% |
| Q4 FY24 | 74.8 | 65.9% | 18.9% | 49.6 | +39% | 1.3 | 96.5% |
| Q1 FY25 | 81.7 | 97.3% | 9.2% | 55.9 | +13% | 5.9 | 94.2% |
| Q2 FY25 | 114.4 | 111.5% | 40.0% | 71.9 | +29% | 19.6 | 98.7% |
| Q3 FY25 | 164.9 | 162.2% | 44.1% | 90.9 | +26% | 51.7 | 99.0% |
| Q4 FY25 | 129.7 | 73.4% | -21.3% | 103.3 | +14% | 3.1 | 98.0% |
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Revenue ($M) | 145.3 | 233.2 | 490.7 |
| YoY Growth | 32.7% | 60.3% | 110.3% |
| Op Margin [GAAP] | -281% | -260% | -12.8% |
| Op Margin [Non-GAAP] | — | — | +8.7% |
| Net Income [GAAP] ($M) | -111.4* | -321.5 | -25.5 |
| EPS [Non-GAAP] | — | — | +$0.91 |
| Annual OCF ($M) | -325.4 | -230.0 | +37.8 |
| Annual SBC ($M) | 44.2 | 36.9 | 44.9 |
*FY23 net income excluding $150.7M discontinued ops gain.
| Metric | Q4 FY24 | Q4 FY25 | Change |
|---|---|---|---|
| Cash + Securities ($M) | 370.7 | 322.8 | -12.9% |
| Convertible Debt ($M) | 379.0 | 311.7 | -17.8% |
| Net Cash ($M) | -8.3 | +11.1 | Inflected positive |
| A/R ($M) | 27.1 | 80.1 | +195% |
| Shares (WA basic, M) | 83.1 | 90.3 | +8.7% |
FILSPARI growth trajectory is genuinely exceptional. $19.8M to $103.3M in 8 quarters. FY25 FILSPARI revenue of $322M represents +144% YoY growth on a product that only launched February 2023. The S-curve here is real and visible — not projected, not modeled, actually happening.
Net product sales are the right metric, and they're clean. Strip out the lumpy license revenue: net product sales were $410.5M in FY25, +81% YoY. Q4 FY25 net product revenue of $126.6M was up +11.8% QoQ from Q3's $113.2M. The underlying product business is not decelerating — the headline Q4 QoQ decline (-21.3%) is entirely a license revenue artifact.
PSF re-acceleration is a strong leading indicator. 908 new patient start forms in Q4, up 24% from 731 in Q3 (which had a slight dip from Q2's 745). All-time high. PSFs take weeks to months to convert to filled prescriptions. This points to a strong Q1 FY26.
The profitability inflection is real. OCF went from -325M(FY23)to−230M (FY24) to +$37.8M (FY25). Non-GAAP net income was 81.1M.GAAPlossnarrowedtojust−25.5M. The company crossed the operational break-even threshold in FY25 — not at some future date, not in a management projection.
Gross margins at 98% are specialty pharma economics at their finest. COGS is essentially non-existent. Every incremental FILSPARI dollar drops to gross profit. This is the kind of margin structure that produces operating leverage fast.
Dilution is slowing. FY25 added only 1.9M net new shares vs 6.0M in FY24 and 12.5M in FY23. The company is approaching self-funding.
KDIGO first-line endorsement (September 2025) is a structural moat. Guidelines change slowly. Doctors follow guidelines. FILSPARI being the only IgAN drug with proven eGFR benefit vs active comparator in the KDIGO guidelines creates a durable prescribing preference.
This is a single-product company with a binary event in 11 days. FILSPARI is 65.6% of FY25 revenue and 100% of the growth story. The FSGS PDUFA on April 13 is the single most important event for the stock. I don't invest based on hope, and I don't make binary bets. If I were sizing this today, the PDUFA date would make me smaller, not larger.
The sNDA extension was a "Major Amendment." The PDUFA moved from January to April 2026. While AdCom removal is often interpreted as bullish, a Major Amendment means the FDA saw something that required additional review. I'd want to understand what was amended before assigning high probability to approval.
SG&A is running ahead of product revenue. Q4 FY25 SG&A was $101.7M, up 46% YoY vs net product sales up 72%. For the full year, SG&A was $337M on $410M of net product sales — an 82% SG&A-to-product-revenue ratio. This is pre-FSGS launch investment. If FSGS is rejected, there's a significant cost structure that needs to come back down.
Accounts receivable grew 2.7x revenue growth in Q4. A/R was $80.1M, up 195% YoY vs 73% revenue growth. That's roughly 22 days of revenue outstanding vs roughly 13 days a year ago. This could be benign (larger institutional accounts, payer mix shifting to Medicaid with longer payment cycles), or it could signal collection issues. Either way, it's worth monitoring.
Competitive intensity is real and increasing. Novartis launched Vanrafia (atrasentan, no REMS) in April 2025. Voyxact (sibeprenlimab) approved November 2025. Fabhalta NDA expected 2026. FILSPARI went from the only approved IgAN therapy to one of four in under two years. The total market is growing, but share compression is inevitable. Vanrafia's no-REMS advantage is a genuine prescriber convenience factor — FILSPARI's REMS simplification (monthly to quarterly monitoring, August 2025) helps but doesn't fully close the gap.
Convertible debt terms remain opaque. 311.7Minconvertiblenotes.Theconversionpriceandmaturitywerenotavailableinthepressreleasedata.Thismatters : iftheconversionpriceisbelowcurrentlevels( 31/share), these notes convert to ~10M additional shares, representing 11% dilution. If above, they remain debt with eventual maturity refinancing needs.
GTN headwind is a quiet growth tax. Mid-20% GTN guided for FY26 vs ~20% in FY25. On an expected 400M + FILSPARIgrosssalesbase, each500bpsofGTNincreasecosts 20M in net revenue. This means FILSPARI needs to grow gross sales ~30% just to deliver 25% net sales growth. Not a deal-breaker, but it suppresses the headline growth rate.
| Metric | Value | Assessment |
|---|---|---|
| P/S (FY25 actual) | 5.7x | Mid-range for commercial biotech |
| P/S (FY26E ~$600M) | 4.7x | Reasonable if FSGS approved |
| P/E (Non-GAAP FY25) | 30.9x | Fair for profitability inflection |
| PEG (P/S / YoY%) | 0.05x | Exceptionally attractive |
| Rule of 40 (FY25) | 117% | Exceptional |
| Market cap | $2.81B | Mid-cap; room to re-rate |
The valuation numbers are objectively cheap. A PEG of 0.05 is rare. A Rule of 40 of 117% is rare. A company growing revenue 110% at 5.7x P/S is rare.
But — and this is important — the market isn't stupid. The discount exists because of the FSGS binary risk. If you assume FSGS is approved (bull case), the stock is significantly undervalued. If FSGS is rejected, the IgAN franchise alone probably supports 2.0 − 2.5Bmarketcap(P/S 4.5xon 500M FY26 product revenue), meaning downside is 10-25%.
The asymmetry here is genuinely favorable: maybe +40-60% upside on FSGS approval vs -10-25% downside on rejection. That's attractive risk/reward math even without a strong view on the FDA outcome.
Revenue growth of 110% massively exceeds P/S of 5.7x. By my revenue-PEG heuristic, the valuation is not the issue here. The question is entirely about the durability of that growth rate.
| Scenario | FY26 Revenue | Implied P/S | Probability (my est.) |
|---|---|---|---|
| Bull (FSGS + strong execution) | $700-800M | 3.5-4.0x | 30% |
| Base (FSGS + moderate GTN) | $550-600M | 4.7-5.1x | 40% |
| Bear (FSGS rejected, IgAN only) | $450-500M | 5.6-6.2x | 30% |
| Probability-weighted | ~$580M | ~4.8x | — |
This is first coverage for me, so I'm establishing baseline beliefs rather than comparing to priors:
Belief 1: FILSPARI's product-market fit is confirmed. The data leaves no room for ambiguity here. $322M in FY25 from a drug launched two years ago, with accelerating PSFs. PROTECT 2-year data and real-world evidence confirm clinical superiority. KDIGO first-line endorsement is the structural moat. Confirmed.
Belief 2: The financial inflection is real but early. OCF positive for the first time. Non-GAAP profitable. GAAP loss only -$25.5M on 491Mrevenue.ButFCFisstillnegative(−20.4M) due to intangible investments. SG&A at 82% of product revenue is high. I'd need to see FY26 deliver GAAP profitability to call this inflection durable.
Belief 3: The single-product concentration is the real risk, not the valuation. FILSPARI is 65.6% of revenue and 100% of the growth story. Tiopronin is declining. License revenue is lumpy and non-repeatable at FY25 levels. If FILSPARI hits any speed bump — competitive share loss, pricing pressure, safety signal — there's no second leg. FSGS approval would partially de-risk this by expanding the addressable market, but it's still the same drug.
Belief 4: The convertible debt is manageable but needs clarity. $311.7M in converts against $322.8M in cash. Net cash positive by $11M. The company isn't in distress. But I'd want to understand the conversion terms before getting comfortable with a large position.
Applying my standard framework:
If I were sizing this today: starter position (3-5%), with explicit plan to add on FSGS approval or trim on rejection.
The binary event makes this a position where I'd want conviction built over time, not enthusiasm getting ahead of the data. The post-PDUFA period — either direction — will tell us what this business really looks like going forward.
I could be wrong about the risk weighting. If FSGS approval odds are genuinely 80%+ (AdCom removal suggests the FDA is comfortable), then waiting to add means paying up 30-50% for certainty. That's a real opportunity cost. But as a retired investor with no income stream, I'd rather pay more for certainty than bet cheaper on uncertainty.
For context, my portfolio typically holds companies at the DDOG, AXON, IOT tier — businesses where I've tracked 8+ quarters, understand the competitive dynamics deeply, and have built conviction through repeated earnings confirmation. TVTX is a first-look where the numbers are superb but the business model (single drug, binary catalyst, pharma pricing dynamics) is outside my typical circle of competence.
The pharma-specific risks (GTN headwinds, REMS complexity, FDA binary events, competitive pipeline from Novartis/Otsuka) are different from the SaaS/software dynamics I track most closely. That warrants additional humility in sizing.
TVTX has an exceptional financial profile — 110% revenue growth, 98% gross margins, OCF inflection, slowing dilution, and a PEG of 0.05. The FILSPARI product launch has been textbook, and the leading indicators (PSFs at all-time highs) point to continued momentum.
The risk isn't the valuation. It's the concentration: one drug, one FDA decision, and increasing competition. The FSGS PDUFA on April 13 is the single variable that determines whether TVTX is a $4B+ company or a $2B company.
For me, the right approach is a starter position with the explicit intent to add on FSGS clarity. The asymmetry is favorable (upside > downside), but the uncertainty is high enough that I don't want to be maximum-sized into a binary event.
Thesis status: New coverage. Establishing at "Intact — conditional on FSGS outcome."
Action: Starter position (3-5%) pre-PDUFA. Add on FSGS approval + Q1 FY26 confirmation. Trim to zero on FSGS rejection + competitive deterioration.
Bear